My intact parathyroid hormone level is 86 pg/mL—what does this indicate and how should I evaluate and manage it?

Evaluation and Management of PTH 86 pg/mL

A PTH of 86 pg/mL requires immediate measurement of serum calcium (corrected and ionized), phosphorus, 25-hydroxyvitamin D, and kidney function to determine whether this represents primary hyperparathyroidism (elevated calcium) or secondary hyperparathyroidism (normal or low calcium). 1

Immediate Diagnostic Workup

Measure the following laboratory tests simultaneously:

• Serum calcium (total corrected and ionized) – This single value determines whether you are dealing with primary versus secondary hyperparathyroidism. Elevated corrected calcium (>10.2 mg/dL) confirms primary hyperparathyroidism because PTH should be suppressed by hypercalcemia. 1

• Serum phosphorus – Typically low-normal (≈2.7–4.6 mg/dL) in primary hyperparathyroidism. 1

• 25-hydroxyvitamin D – Vitamin D deficiency is the most common cause of secondary hyperparathyroidism and must be excluded before diagnosing primary disease. 1

• Serum creatinine and eGFR – PTH rises when eGFR falls below 60 mL/min/1.73 m², supporting a secondary renal etiology. 1

• 24-hour urine calcium – Hypercalciuria (>300 mg/24h) identifies patients who may benefit from surgery. 1

Interpretation Based on Calcium Level

If Calcium is Elevated (>10.2 mg/dL): Primary Hyperparathyroidism

This confirms primary hyperparathyroidism because the parathyroid glands are autonomously secreting PTH despite hypercalcemia. 1 The PTH should be suppressed below 20 pg/mL in the presence of hypercalcemia; any detectable PTH is "inappropriately normal" and diagnostic. 2, 3

Proceed with the following:

• Obtain pre-operative localization imaging (neck ultrasound and/or 99mTc-sestamibi SPECT/CT) only after biochemical confirmation to enable minimally invasive parathyroidectomy. 1

• Refer to endocrinology and an experienced parathyroid surgeon if any of the following surgical indications are present: 1

  • Corrected calcium >1 mg/dL above upper limit of normal (≈>11.2 mg/dL)
  • Age <50 years
  • eGFR <60 mL/min/1.73 m²
  • Osteoporosis (T-score ≤-2.5 at any site)
  • History of kidney stones or nephrocalcinosis
  • 24-hour urine calcium >300 mg
  • Symptomatic disease (bone pain, fractures, neurocognitive impairment, depression, "brain fog")

• If surgery is not pursued, monitor with: 1

  • Serum calcium and phosphorus every 3 months
  • Annual bone mineral density assessment
  • Annual renal ultrasound to screen for stones or nephrocalcinosis
  • Maintain 25-OH vitamin D >20 ng/mL with supplementation
  • Ensure dietary calcium 1,000–1,200 mg/day (do not exceed 2,000 mg/day total)

If Calcium is Normal or Low: Secondary Hyperparathyroidism

Systematically exclude all secondary causes before considering normocalcemic primary hyperparathyroidism: 1

1. Vitamin D deficiency – Supplement if 25-OH vitamin D <30 ng/mL. Vitamin D deficiency is the leading cause of secondary hyperparathyroidism, and vitamin D-replete individuals have PTH concentrations 20% lower than those with unknown vitamin D status. 1

2. Chronic kidney disease – If eGFR <60 mL/min/1.73 m², this explains the PTH elevation. In dialysis patients, target PTH is 150–300 pg/mL; do not suppress PTH below 150 pg/mL as this predisposes to adynamic bone disease. 4, 1

3. Inadequate dietary calcium – Ensure intake of 1,000–1,200 mg/day. Low urinary calcium (<100 mg/24h) suggests calcium deprivation. 1

4. Medications – Review for thiazides, lithium, or other drugs affecting calcium/PTH homeostasis. 1

After excluding all secondary causes, persistent elevated PTH with normal calcium defines normocalcemic primary hyperparathyroidism, which carries a risk profile comparable to hypercalcemic disease (stones, osteoporosis, neurocognitive symptoms). 1, 5

Critical Assay Considerations

PTH assays vary up to 47% between generations; always apply the laboratory-specific reference range rather than generic cut-offs. 4, 1 Normal PTH for healthy adults is roughly 15–65 pg/mL, but this varies by assay. 1

For optimal accuracy: 1

• Collect PTH in EDTA plasma kept at 4°C (not room-temperature serum)
• Recognize that biotin supplementation interferes with PTH immunoassays and can produce spurious results
• Biological variation of PTH is substantial (≈20% in healthy individuals); a change >54% is required to be clinically meaningful 1

Common Pitfalls to Avoid

• Do not assume an isolated elevated PTH indicates primary hyperparathyroidism; the calcium level is essential for classification. 1

• Do not initiate active vitamin D (calcitriol) when phosphorus >6.5 mg/dL or calcium >10.2 mg/dL to prevent vascular calcification. 1

• Do not order parathyroid imaging before confirming the diagnosis biochemically; imaging is for surgical planning, not diagnosis. 1

• In chronic kidney disease, do not suppress PTH below 150 pg/mL, as this predisposes to adynamic bone disease. 4, 1

• Recognize that PTH increases with age (especially >60 years), higher BMI, and is higher in Black individuals; interpret results using appropriate reference ranges. 1

Monitoring During Treatment

If vitamin D supplementation is initiated for deficiency: 1

• Measure calcium and phosphorus every 2 weeks for the first month, then monthly
• Measure PTH monthly for the first 3 months, then every 3 months once stable
• Discontinue active vitamin D immediately if calcium rises above 10.2 mg/dL

If chronic kidney disease is present and PTH is 86 pg/mL (below the dialysis target of 150–300 pg/mL), avoid further suppression and maintain the current level. 4, 6